1. Home
  2. EVAX vs ENSC Comparison

EVAX vs ENSC Comparison

Compare EVAX & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EVAX

Evaxion Biotech

HOLD

Current Price

$5.98

Market Cap

42.7M

Sector

Health Care

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.17

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EVAX
ENSC
Founded
2008
2003
Country
Denmark
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.7M
6.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
EVAX
ENSC
Price
$5.98
$1.17
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$12.33
N/A
AVG Volume (30 Days)
100.4K
417.4K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$7,650,000.00
$4,487,973.00
Revenue This Year
$128.77
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
132.17
1.51
52 Week Low
$1.20
$1.26
52 Week High
$12.15
$10.96

Technical Indicators

Market Signals
Indicator
EVAX
ENSC
Relative Strength Index (RSI) 53.56 26.87
Support Level $5.72 $1.26
Resistance Level $6.70 $1.69
Average True Range (ATR) 0.51 0.15
MACD 0.07 -0.03
Stochastic Oscillator 56.08 5.63

Price Performance

Historical Comparison
EVAX
ENSC

About EVAX Evaxion Biotech

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: